Interesting Image

Peptide Receptor Radionuclide Therapy with ¹⁷⁷Lu-DOTATATE in a Case of Concurrent Neuroendocrine Tumors and Meningioma: Achieving Two Things in a Single Action

10.4274/mirt.galenos.2020.69783

• Majid Assadi
• Seyed Javad Rekabpour
• Abdullatif Amini
• Habibollah Dadgar
• Reza Nemati
• Ali Gholamrezanezhad
• Iraj Nabipour
• Esmail Jafari
• Hojjat Ahmadzadehfar

Received Date: 10.08.2019 Accepted Date: 14.04.2020 Mol Imaging Radionucl Ther 2021;30(2):107-109 PMID: 34082512

• Abstract
• Full Text
• Video - Image
• References
• 12
• 1150

We present a partial response of peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE in a case of concurrent neuroendocrine tumors (NETs) and meningioma. In addition to the valuable role of PRRT in inoperable NETs, it has been demonstrated that this treatment can be a promising therapy for progressive meningioma, especially in patients with low grade and refractory to standard regime.

Keywords: 68Ga-DOTATATE PET/MRI, PRRT, neuroendocrine tumor, 18F-FDG-PET/CT

Ethics

Informed Consent: Written informed consent of the patient was obtained from the patient.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices: M.A., S.J.R., A.A., H.D., R.N., I.N., E.J., H.A., Concept: M.A., A.G., H.A., Design: M.A., E.J., Data Collection or Processing: M.A., E.J., H.D., Analysis or Interpretation: M.A., E.J., H.D., R.N., Literature Search: M.A., E.J., Writing: M.A., E.J., H.A.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

Images

1. Makis W, McCann K, McEwan AJ. Rhabdoid papillary meningioma treated with 177Lu DOTATATE PRRT. Clin Nucl Med 2015;40:237-240.
2. Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, Baio SM, Aricò D, Sansovini M, Paganelli G. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging 2009;36:1407-1416.
3. Carlsen EA, Fazio N, Granberg D, Grozinsky-Glasberg S, Ahmadzadehfar H, Grana CM, Zandee WT, Cwikla J, Walter MA, Oturai PS, Rinke A, Weaver A, Frilling A, Gritti S, Arveschoug AK, Meirovitz A, Knigge U, Sorbye H. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. Endocr Relat Cancer 2019;26:227-239.
4. Sommerauer M, Burkhardt JK, Frontzek K, Rushing E, Buck A, Krayenbuehl N, Weller M, Schaefer N, Kuhn FP. 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? Neuro Oncol 2016;18:1021-1027.
5. Seystahl K, Stoecklein V, Schüller U, Rushing E, Nicolas G, Schäfer N, Ilhan H, Pangalu A, Weller M, Tonn JC, Sommerauer M, Albert NL. Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. Neuro Oncol 2016;18:1538-1547.